# Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

> **NCT04629976** · PHASE1 · COMPLETED · sponsor: **Nucorion Pharmaceuticals, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** NCO-48 Fumarate 4 mg
- **DRUG:** NCO-48 Fumarate 20 mg
- **DRUG:** Tenofovir Alafenamide 25 mg

## Key facts

- **NCT ID:** NCT04629976
- **Lead sponsor:** Nucorion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-12
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-12-28
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629976, "Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04629976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*